Table 5.

Glutamine synthetase immunohistochemistry

Staining pattern	heterogeneous	Focal/patchy	Diffuse	Negative
N	18 (24.3%)	5 (6.8%)	50 (67.6%)	1 (1.4%)
Age (year)	32–83 (median 70.5)	38 – 82 (median 65)	26–80 (median 65.5)	18
Male: Female	10: 8	3: 2	30: 20	M
Viral hepatitis or alcoholic liver disease	2	0	4	0
Diabetes mellitus	4/15 (26.7)	2/6 (33.3%)	10/45 (22.2%)	0
Body mass index (available n)	10	5	38	1
< 25	3 (30.0%)	2 (40.0%)	13 (34.2%)	1
25 – 29	4 (40.0%)	1 (20.0%)	13 (34.2%)	0
≥ 30	3 (30.0%)	2 (40.0%)	12 (31.6%)	0
Metabolic Syndrome	3/6 (50.0%)	1/2 (50.0%)	11/18 (61.1%)	N/A
Size (cm)	2.5 – 15 (mean 7.9)	4.5 – 17 (mean 8.0)	1.3 – 24 (mean 8.1)	11.5
Multifocality	6 (33.3%)	0	14 (28.0%)	0
Tumor Grade	I: 3 (16.7%),	I: 0,	I: 7 (14.0%),	III
	II: 10 (55.6%),	II: 4 (80.0%),	II: 21 (42.0%),
	III: 2 (11.1%),	III: 0,	III: 14 (28.0%),
	IV: 3 (16.7%)	IV: 1 (20.0%)	IV: 8 (16.0%)
Steatosis (tumor)	4 (22.2%)	0	8 (16.0%)	0
Steatosis (liver)	3 (16.7%)	1 (20.0%)	11 (22.0%)	0
Fibrosis*	0: 2 (11.1%),*	0: 5 (100.0%),*	0: 13 (26.0%),*	2
	1: 5 (27.8%),	1: 0,	1: 14 (28.0%),
	2: 8 (44.4%),	2: 0,	2: 18 (36.0%),
	3: 3 (16.7%)	3:0	3: 5 (10.0%)

^*p < 0.05.